Skip to main content
Erschienen in: Pathology & Oncology Research 2/2009

01.06.2009 | Original Paper

Increased p53 Expression in the Malignant Transformation of Barrett’s Esophagus is Accompanied by an Upward Shift of the Proliferative Compartment

verfasst von: Istvan Hritz, Hajnalka Gyorffy, Bela Molnar, Gabor Lakatos, Ferenc Sipos, Istvan Pregun, Mark Juhasz, Laszlo Pronai, Zsuzsa Schaff, Zsolt Tulassay, Laszlo Herszenyi

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Neoplastic progression in Barrett’s esophagus (BE) occurs by a multistep process associated with early molecular and morphological changes. This study evaluated cell proliferation and p53 expression and their correlation in the development and progression of esophageal adenocarcinoma. PCNA and p53 expressions were analyzed in biopsy samples by immunohistochemistry including patients with reflux esophagitis, BE, BE with concomitant esophagitis, Barrett’s dysplasia, esophageal adenocarcinoma and a control group without any histological changes. Progressive increase in cell proliferation and p53 expression was found in the sequence of malignant transformation of the esophageal mucosa. While cell proliferation was significantly lower in the control group compared with all other groups, there was no increase in p53 expression of esophageal tissues that were negative for dysplasia. Dysplastic BE tissues revealed significantly higher cell proliferation and p53 expression levels compared to BE, reflux esophagitis or BE with concomitant esophagitis. Both, cell proliferation and p53 expression were significantly higher in adenocarcinoma compared to BE or Barrett’s dysplasia. Interestingly, while just BE with concomitant esophagitis showed significantly higher p53 expression levels than BE, both, BE with concomitant esophagitis and reflux esophagitis revealed significantly higher cell proliferation levels compared to BE. Alterations of cell proliferation and p53 expression showed a strong correlation. Simultaneous activation of cell proliferation and p53 expression strongly suggest their association with esophageal epithelial tumor genesis and particularly, their specific role in the biology of esophageal adenocarcinoma. Quantification of these parameters in BE is thought to be useful to identify patients at higher risk for progression to adenocarcinoma.
Literatur
1.
Zurück zum Zitat Bosetti C, Levi F, Ferlay J et al (2008) Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 122(5):1118–1129CrossRefPubMed Bosetti C, Levi F, Ferlay J et al (2008) Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 122(5):1118–1129CrossRefPubMed
2.
Zurück zum Zitat Wu X, Chen VW, Andrews PA et al (2007) Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control 18(6):585–593CrossRefPubMed Wu X, Chen VW, Andrews PA et al (2007) Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control 18(6):585–593CrossRefPubMed
3.
Zurück zum Zitat Fléjou JF (2005) Barrett’s oesophagus: from metaplasia to dysplasia and cancer. Gut 54(Suppl 1):i6–i12CrossRefPubMed Fléjou JF (2005) Barrett’s oesophagus: from metaplasia to dysplasia and cancer. Gut 54(Suppl 1):i6–i12CrossRefPubMed
4.
Zurück zum Zitat Spechler SJ, Goyal RK (1986) Barrett’s esophagus. N Engl J Med 315(6):362–371PubMed Spechler SJ, Goyal RK (1986) Barrett’s esophagus. N Engl J Med 315(6):362–371PubMed
5.
Zurück zum Zitat Westhoff B, Brotze S, Weston A et al (2005) The frequency of Barrett’s esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 61(2):226–231CrossRefPubMed Westhoff B, Brotze S, Weston A et al (2005) The frequency of Barrett’s esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 61(2):226–231CrossRefPubMed
6.
Zurück zum Zitat Jankowski JA, Harrison RF, Perry I et al (2000) Barrett’s metaplasia. Lancet 356(9247):2079–2085CrossRefPubMed Jankowski JA, Harrison RF, Perry I et al (2000) Barrett’s metaplasia. Lancet 356(9247):2079–2085CrossRefPubMed
7.
Zurück zum Zitat Shaheen NJ (2005) Advances in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology 128(6):1554–1566CrossRefPubMed Shaheen NJ (2005) Advances in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology 128(6):1554–1566CrossRefPubMed
8.
Zurück zum Zitat Srivastava A, Hornick JL, Li X et al (2007) Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus. Am J Gastroenterol 102(3):483–493CrossRefPubMed Srivastava A, Hornick JL, Li X et al (2007) Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus. Am J Gastroenterol 102(3):483–493CrossRefPubMed
9.
Zurück zum Zitat Schlansky B, Dimarino AJ Jr, Loren D et al (2006) A survey of oesophageal cancer: pathology, stage and clinical presentation. Aliment Pharmacol Ther 23(5):587–593CrossRefPubMed Schlansky B, Dimarino AJ Jr, Loren D et al (2006) A survey of oesophageal cancer: pathology, stage and clinical presentation. Aliment Pharmacol Ther 23(5):587–593CrossRefPubMed
10.
Zurück zum Zitat Skacel M, Petras RE, Gramlich TL et al (2000) The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol 95(12):3383–3387CrossRefPubMed Skacel M, Petras RE, Gramlich TL et al (2000) The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol 95(12):3383–3387CrossRefPubMed
11.
Zurück zum Zitat McManus DT, Olaru A, Meltzer SJ (2004) Biomarkers of esophageal adenocarcinoma and Barrett’s esophagus. Cancer Res 64(5):1561–1569CrossRefPubMed McManus DT, Olaru A, Meltzer SJ (2004) Biomarkers of esophageal adenocarcinoma and Barrett’s esophagus. Cancer Res 64(5):1561–1569CrossRefPubMed
12.
Zurück zum Zitat Younes M, Ertan A, Lechago LV et al (1997) p53 protein accumulation is a specific marker of malignant potential in Barrett’s metaplasia. Dig Dis Sci 42(4):697–701CrossRefPubMed Younes M, Ertan A, Lechago LV et al (1997) p53 protein accumulation is a specific marker of malignant potential in Barrett’s metaplasia. Dig Dis Sci 42(4):697–701CrossRefPubMed
13.
Zurück zum Zitat Hong MK, Laskin WB, Herman BE et al (1995) Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett’s esophagus. Cancer 75(2):423–429CrossRefPubMed Hong MK, Laskin WB, Herman BE et al (1995) Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett’s esophagus. Cancer 75(2):423–429CrossRefPubMed
14.
Zurück zum Zitat Prelich G, Tan CK, Kostura M et al (1987) Functional identity of proliferating cell nuclear antigen and a DNA polymerase auxiliary protein. Nature 326(6112):517–520CrossRefPubMed Prelich G, Tan CK, Kostura M et al (1987) Functional identity of proliferating cell nuclear antigen and a DNA polymerase auxiliary protein. Nature 326(6112):517–520CrossRefPubMed
15.
Zurück zum Zitat Reid BJ, Sanchez CA, Blount PL et al (1993) Barrett’s esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105(1):119–129PubMed Reid BJ, Sanchez CA, Blount PL et al (1993) Barrett’s esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105(1):119–129PubMed
16.
Zurück zum Zitat el-Deiry WS, Harper JW, O’Connor PM et al (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54(5):1169–1174PubMed el-Deiry WS, Harper JW, O’Connor PM et al (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54(5):1169–1174PubMed
17.
Zurück zum Zitat Ramel S, Reid BJ, Sanchez CA et al (1992) Evaluation of p53 protein expression in Barrett’s esophagus by two-parameter flow cytometry. Gastroenterology 102(4 Pt 1):1220–1228PubMed Ramel S, Reid BJ, Sanchez CA et al (1992) Evaluation of p53 protein expression in Barrett’s esophagus by two-parameter flow cytometry. Gastroenterology 102(4 Pt 1):1220–1228PubMed
18.
Zurück zum Zitat Wang DY, Xiang YY, Tanaka M et al (1994) High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 74(12):3089–3096CrossRefPubMed Wang DY, Xiang YY, Tanaka M et al (1994) High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 74(12):3089–3096CrossRefPubMed
19.
Zurück zum Zitat Slade N, Moll UM (2003) Mutational analysis of p53 in human tumors: immunocytochemistry. Methods Mol Biol 234:231–243PubMed Slade N, Moll UM (2003) Mutational analysis of p53 in human tumors: immunocytochemistry. Methods Mol Biol 234:231–243PubMed
20.
Zurück zum Zitat Bian YS, Osterheld MC, Bosman FT et al (2001) p53 gene mutation and protein accumulation during neoplastic progression in Barrett’s esophagus. Mod Pathol 14(5):397–403CrossRefPubMed Bian YS, Osterheld MC, Bosman FT et al (2001) p53 gene mutation and protein accumulation during neoplastic progression in Barrett’s esophagus. Mod Pathol 14(5):397–403CrossRefPubMed
21.
Zurück zum Zitat Geboes K, Van Eyken P et al (2000) The diagnosis of dysplasia and malignancy in Barrett’s oesophagus. Histopathology 37(2):99–107CrossRefPubMed Geboes K, Van Eyken P et al (2000) The diagnosis of dysplasia and malignancy in Barrett’s oesophagus. Histopathology 37(2):99–107CrossRefPubMed
22.
Zurück zum Zitat Polkowski W, van Lanschot JJ, ten Kate FJ et al (1995) The value of p53 and Ki67 as markers for tumour progression in the Barrett’s dysplasia–carcinoma sequence. Surg Oncol 4(3):163–171PubMedCrossRef Polkowski W, van Lanschot JJ, ten Kate FJ et al (1995) The value of p53 and Ki67 as markers for tumour progression in the Barrett’s dysplasia–carcinoma sequence. Surg Oncol 4(3):163–171PubMedCrossRef
23.
Zurück zum Zitat Herszenyi L, Hritz I, Pregun I et al (2007) Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol 13(5):676–682PubMed Herszenyi L, Hritz I, Pregun I et al (2007) Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol 13(5):676–682PubMed
24.
Zurück zum Zitat Hritz I, Kuester D, Vieth M et al (2006) Secretory leukocyte protease inhibitor expression in various types of gastritis: a specific role of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 18(3):277–282CrossRefPubMed Hritz I, Kuester D, Vieth M et al (2006) Secretory leukocyte protease inhibitor expression in various types of gastritis: a specific role of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 18(3):277–282CrossRefPubMed
25.
Zurück zum Zitat Hritz I, Herszenyi L, Molnar B et al (2005) Proton pump inhibitor co-therapy normalizes the increased cell turnover of the gastric mucosa both in NSAID and selective COX-2 users. Int J Immunpathol Pharmacol 18(1):75–84 Hritz I, Herszenyi L, Molnar B et al (2005) Proton pump inhibitor co-therapy normalizes the increased cell turnover of the gastric mucosa both in NSAID and selective COX-2 users. Int J Immunpathol Pharmacol 18(1):75–84
26.
Zurück zum Zitat Hritz I, Herszenyi L, Molnar B et al (2005) Long-term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression. World J Gastroenterol 11(30):4721–4726PubMed Hritz I, Herszenyi L, Molnar B et al (2005) Long-term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression. World J Gastroenterol 11(30):4721–4726PubMed
27.
Zurück zum Zitat Fitzgerald RC et al (2006) Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut 55(12):1810–1820CrossRefPubMed Fitzgerald RC et al (2006) Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut 55(12):1810–1820CrossRefPubMed
28.
Zurück zum Zitat Reid BJ, Weinstein WM, Lewin KJ et al (1988) Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophagus without grossly recognizable neoplastic lesions. Gastroenterology 94(1):81–90PubMed Reid BJ, Weinstein WM, Lewin KJ et al (1988) Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophagus without grossly recognizable neoplastic lesions. Gastroenterology 94(1):81–90PubMed
29.
Zurück zum Zitat Theisen J, Nigro JJ, DeMeester TR et al (2004) Chronology of the Barrett’s metaplasia–dysplasia–carcinoma sequence. Dis Esophagus 17(1):67–70CrossRefPubMed Theisen J, Nigro JJ, DeMeester TR et al (2004) Chronology of the Barrett’s metaplasia–dysplasia–carcinoma sequence. Dis Esophagus 17(1):67–70CrossRefPubMed
30.
Zurück zum Zitat Kleeff J, Friess H, Liao Q et al (2002) Immunohistochemical presentation in non-malignant and malignant Barrett’s epithelium. Dis Esophagus 15(1):10–15CrossRefPubMed Kleeff J, Friess H, Liao Q et al (2002) Immunohistochemical presentation in non-malignant and malignant Barrett’s epithelium. Dis Esophagus 15(1):10–15CrossRefPubMed
31.
Zurück zum Zitat Biasco G et al (2004) Cell proliferation and differentiation in familial adenomatous polyposis (FAP). Hum Pathol 35(12):1573CrossRefPubMed Biasco G et al (2004) Cell proliferation and differentiation in familial adenomatous polyposis (FAP). Hum Pathol 35(12):1573CrossRefPubMed
32.
Zurück zum Zitat Scalmati A, Roncucci L, Ghidini G et al (1990) Epithelial cell kinetics in the remaining colorectal mucosa after surgery for cancer of the large bowel. Cancer Res 50(24):7937–7941PubMed Scalmati A, Roncucci L, Ghidini G et al (1990) Epithelial cell kinetics in the remaining colorectal mucosa after surgery for cancer of the large bowel. Cancer Res 50(24):7937–7941PubMed
33.
Zurück zum Zitat Bechi P, Balzi M, Becciolini A et al (1996) Helicobacter pylori and cell proliferation of the gastric mucosa: possible implications for gastric carcinogenesis. Am J Gastroenterol 91(2):271–276PubMed Bechi P, Balzi M, Becciolini A et al (1996) Helicobacter pylori and cell proliferation of the gastric mucosa: possible implications for gastric carcinogenesis. Am J Gastroenterol 91(2):271–276PubMed
34.
Zurück zum Zitat Peters FT, Ganesh S, Kuipers EJ et al (1998) Epithelial cell proliferative activity of Barrett’s esophagus: methodology and correlation with traditional cancer risk markers. Dig Dis Sci 43(7):1501–1506CrossRefPubMed Peters FT, Ganesh S, Kuipers EJ et al (1998) Epithelial cell proliferative activity of Barrett’s esophagus: methodology and correlation with traditional cancer risk markers. Dig Dis Sci 43(7):1501–1506CrossRefPubMed
35.
Zurück zum Zitat Rioux-Leclercq N, Turlin B, Sutherland F et al (1999) Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia–carcinoma sequence of Barrett’s esophagus. Oncol Rep 6(4):877–882PubMed Rioux-Leclercq N, Turlin B, Sutherland F et al (1999) Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia–carcinoma sequence of Barrett’s esophagus. Oncol Rep 6(4):877–882PubMed
36.
Zurück zum Zitat Kim R, Clarke MR, Melhem MF et al (1997) Expression of p53, PCNA, and CerbB-2 in Barrett’s metaplasia and adenocarcinoma. Dig Dis Sci 42(12):2453–2462CrossRefPubMed Kim R, Clarke MR, Melhem MF et al (1997) Expression of p53, PCNA, and CerbB-2 in Barrett’s metaplasia and adenocarcinoma. Dig Dis Sci 42(12):2453–2462CrossRefPubMed
37.
Zurück zum Zitat Kataoka H, Joh T, Kasugai K et al (1997) Mitogenic properties of human gastric juice. Dig Dis Sci 42(8):1747–1754CrossRefPubMed Kataoka H, Joh T, Kasugai K et al (1997) Mitogenic properties of human gastric juice. Dig Dis Sci 42(8):1747–1754CrossRefPubMed
38.
Zurück zum Zitat Lagergren J, Bergstrom R, Lindgren A et al (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340(11):825–831CrossRefPubMed Lagergren J, Bergstrom R, Lindgren A et al (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340(11):825–831CrossRefPubMed
39.
Zurück zum Zitat Shaheen N, Ransohoff DF et al (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287(15):1972–1981CrossRefPubMed Shaheen N, Ransohoff DF et al (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287(15):1972–1981CrossRefPubMed
40.
Zurück zum Zitat Peters FT, Ganesh S, Kuipers EJ et al (2000) Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol 35(12):1238–1244CrossRefPubMed Peters FT, Ganesh S, Kuipers EJ et al (2000) Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol 35(12):1238–1244CrossRefPubMed
41.
Zurück zum Zitat Ireland AP, Clark GW, DeMeester TR (1997) Barrett’s esophagus. The significance of p53 in clinical practice. Ann Surg 225(1):17–30CrossRefPubMed Ireland AP, Clark GW, DeMeester TR (1997) Barrett’s esophagus. The significance of p53 in clinical practice. Ann Surg 225(1):17–30CrossRefPubMed
42.
Zurück zum Zitat Flejou JF, Potet F, Muzeau F et al (1993) Overexpression of p53 protein in Barrett’s syndrome with malignant transformation. J Clin Pathol 46(4):330–333CrossRefPubMed Flejou JF, Potet F, Muzeau F et al (1993) Overexpression of p53 protein in Barrett’s syndrome with malignant transformation. J Clin Pathol 46(4):330–333CrossRefPubMed
43.
Zurück zum Zitat Schneider PM, Casson AG, Levin B et al (1996) Mutations of p53 in Barrett’s esophagus and Barrett’s cancer: a prospective study of 98 cases. J Thorac Cardiovasc Surg 111(2):323–331CrossRefPubMed Schneider PM, Casson AG, Levin B et al (1996) Mutations of p53 in Barrett’s esophagus and Barrett’s cancer: a prospective study of 98 cases. J Thorac Cardiovasc Surg 111(2):323–331CrossRefPubMed
44.
Zurück zum Zitat Hornick JL, Mino-Kenudson M, Lauwers GY et al (2008) Buried Barrett’s epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol 103(1):38–47PubMed Hornick JL, Mino-Kenudson M, Lauwers GY et al (2008) Buried Barrett’s epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol 103(1):38–47PubMed
45.
Zurück zum Zitat Younes M, Lebovitz RM, Lechago LV et al (1993) p53 protein accumulation in Barrett’s metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 105(6):1637–1642PubMed Younes M, Lebovitz RM, Lechago LV et al (1993) p53 protein accumulation in Barrett’s metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 105(6):1637–1642PubMed
46.
Zurück zum Zitat Sun WH, Sun YL, Fang RN et al (2005) Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol 35(12):707–713CrossRefPubMed Sun WH, Sun YL, Fang RN et al (2005) Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol 35(12):707–713CrossRefPubMed
47.
Zurück zum Zitat Takeuchi T, Hisanaga M, Nagao M et al (2004) The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10(16):5572–5579CrossRefPubMed Takeuchi T, Hisanaga M, Nagao M et al (2004) The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10(16):5572–5579CrossRefPubMed
48.
Zurück zum Zitat Samantaray S, Sharma R, Chattopadhyaya TK et al (2004) Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 130(1):37–44CrossRefPubMed Samantaray S, Sharma R, Chattopadhyaya TK et al (2004) Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 130(1):37–44CrossRefPubMed
Metadaten
Titel
Increased p53 Expression in the Malignant Transformation of Barrett’s Esophagus is Accompanied by an Upward Shift of the Proliferative Compartment
verfasst von
Istvan Hritz
Hajnalka Gyorffy
Bela Molnar
Gabor Lakatos
Ferenc Sipos
Istvan Pregun
Mark Juhasz
Laszlo Pronai
Zsuzsa Schaff
Zsolt Tulassay
Laszlo Herszenyi
Publikationsdatum
01.06.2009
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2009
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9095-z

Weitere Artikel der Ausgabe 2/2009

Pathology & Oncology Research 2/2009 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.